[ad_1]
Grail Inc. reports first-quarter earnings Tuesday after the market close, with investors focused on whether the cancer-detection company can sustain commercial momentum following a high-profile clinical trial setback that sent shares tumbling earlier this year.
Analysts expect revenue of $40.4 million, representing 26.88% year-over-year growth for the quarter ended March 2026. However, that would mark a sequential decline from the $43.6 million reported in the fourth quarter. No consensus EPS estimate is available for the quarter. Revenue estimates have remained largely stable, with the 60-day trend showing a modest 0.93% increase.
Analysts rate the stock a Buy, with a mean price target of $67.71, implying 21.66% upside from Monday’s close of $55.66. The $2.28 billion company counts four Buy ratings and four Hold ratings among the eight analysts covering it.
Wall Street remains divided on Grail’s prospects following February’s NHS-Galleri trial results. While the landmark 142,000-patient study missed its primary endpoint of reducing combined Stage III-IV cancer diagnoses, the company highlighted a substantial reduction in Stage IV cancers specifically and a four-fold increase in cancer detection rates. Shares plunged 47% in after-hours trading on the announcement.
“We view the Galleri test as a leader in MCED given its large clinical trial catalog,” Mizuho analyst Bradley Bowers wrote in initiating coverage with a Neutral rating in April. However, he noted that “early physician feedback questions competitive advantage” and projected “MCED volume inflection is more likely in 2027, after FDA approval.”
What Investors Are Watching
The central question is how management characterizes the NHS-Galleri data ahead of detailed presentations at the ASCO Annual Meeting later this month. Grail will present additional findings from both NHS-Galleri and the PATHFINDER 2 study on May 30-31, which could reshape the narrative around clinical utility.
Investors will also look for updates on the FDA approval timeline. Grail submitted the final module of its Premarket Approval application in January 2026, and analysts anticipate a decision in late 2026 or early 2027. Guggenheim’s Subbu Nambi maintains that Grail “will be the first FDA approved MCED test on the market.”
The regulatory outlook improved significantly in February when the Nancy Gardner Sewell Medicare MCED Screening Coverage Act was signed into law, establishing a pathway for Medicare coverage beginning in 2028 following FDA approval. Piper Sandler called the legislation “a favorable reimbursement pathway.”
In the fourth quarter, Grail reported a loss of $2.44 per share, significantly better than the $4.01 consensus estimate, delivering a 39.15% earnings surprise. The company has narrowed losses substantially, with diluted EPS improving 82.51% year-over-year.
Tonight’s results will offer insight into whether Grail’s commercial trajectory and regulatory progress can overcome concerns about the trial’s primary endpoint miss and justify the company’s pivot from clinical validation to market adoption.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
[ad_2]
Source link
